D J Slamon

Activity of the multikinase inhibitor dasatinib against ovarian cancer cells

J. Brugge, G. Yang, J. Dering, 2009, British Journal of Cancer.

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.

D Tripathy, B. Weber, J. Baselga, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry.

D. Slamon, R. Seshadri, G. Pauletti, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification of differentially expressed genes associated with HER-2/neu overexpression in human breast cancer cells.

D. Slamon, S. Wong, D. Slamon, 1999, Nucleic acids research.